Reinier G S Meester1, Iris Lansdorp-Vogelaar2, Sidney J Winawer3, Ann G Zauber3, Amy B Knudsen4, Uri Ladabaum5. 1. Erasmus MC University Medical Center, Rotterdam, the Netherlands, and Stanford University, Stanford, California (R.G.M.). 2. Erasmus MC University Medical Center, Rotterdam, the Netherlands (I.L.). 3. Memorial Sloan Kettering Cancer Center, New York, New York (S.J.W., A.G.Z.). 4. Massachusetts General Hospital, Boston, Massachusetts (A.B.K.). 5. Stanford University, Stanford, California (U.L.).
Abstract
Background: Surveillance of patients with colorectal adenomas has limited long-term evidence to support current practice. Objective: To compare the lifetime benefits and costs of high- versus low-intensity surveillance. Design: Microsimulation model. Data Sources: U.S. cancer registry, cost data, and published literature. Target Population: U.S. patients aged 50, 60, or 70 years with low-risk adenomas (LRAs) (1 to 2 small adenomas) or high-risk adenomas (HRAs) (3 to 10 small adenomas or ≥1 large adenoma) removed after screening with colonoscopy or fecal immunochemical testing (FIT). Time Horizon: Lifetime. Perspective: Societal. Intervention: No further screening or surveillance, routine screening after 10 years, low-intensity surveillance (10 years after LRA removal and 5 years after HRA removal), and high-intensity surveillance (5 years after LRA removal and 3 years after HRA removal). Outcome Measures: Colorectal cancer (CRC) incidence and incremental cost-effectiveness. Results of Base-Case Analysis: Without surveillance or screening, lifetime CRC incidence for patients aged 50 years was 10.9% after LRA removal and 17.2% after HRA removal at screening colonoscopy. Subsequent colonoscopic screening, low-intensity surveillance, or high-intensity surveillance decreased incidence by 39%, 46% to 48%, and 55% to 56%, respectively. Incidence of CRC and surveillance benefits were higher for adenomas detected at FIT screening and lower for older patients. High-intensity surveillance cost less than $30 000 per quality-adjusted life-year (QALY) gained compared with low-intensity surveillance. Results of Sensitivity Analysis: High-intensity surveillance cost less than $100 000 per QALY gained in most alternative scenarios for adenoma recurrence, CRC incidence, longevity, quality of life, screening ages, surveillance ages, test performance, disutilities, and cost. Limitation: Few surveillance outcome data exist. Conclusion: The model suggests that high-intensity surveillance as recommended in the United States provides modest but clinically relevant benefits over low-intensity surveillance at acceptable cost. Primary Funding Source: National Cancer Institute.
Background: Surveillance of patients with colorectal adenomas has limited long-term evidence to support current practice. Objective: To compare the lifetime benefits and costs of high- versus low-intensity surveillance. Design: Microsimulation model. Data Sources: U.S. cancer registry, cost data, and published literature. Target Population: U.S. patients aged 50, 60, or 70 years with low-risk adenomas (LRAs) (1 to 2 small adenomas) or high-risk adenomas (HRAs) (3 to 10 small adenomas or ≥1 large adenoma) removed after screening with colonoscopy or fecal immunochemical testing (FIT). Time Horizon: Lifetime. Perspective: Societal. Intervention: No further screening or surveillance, routine screening after 10 years, low-intensity surveillance (10 years after LRA removal and 5 years after HRA removal), and high-intensity surveillance (5 years after LRA removal and 3 years after HRA removal). Outcome Measures: Colorectal cancer (CRC) incidence and incremental cost-effectiveness. Results of Base-Case Analysis: Without surveillance or screening, lifetime CRC incidence for patients aged 50 years was 10.9% after LRA removal and 17.2% after HRA removal at screening colonoscopy. Subsequent colonoscopic screening, low-intensity surveillance, or high-intensity surveillance decreased incidence by 39%, 46% to 48%, and 55% to 56%, respectively. Incidence of CRC and surveillance benefits were higher for adenomas detected at FIT screening and lower for older patients. High-intensity surveillance cost less than $30 000 per quality-adjusted life-year (QALY) gained compared with low-intensity surveillance. Results of Sensitivity Analysis: High-intensity surveillance cost less than $100 000 per QALY gained in most alternative scenarios for adenoma recurrence, CRC incidence, longevity, quality of life, screening ages, surveillance ages, test performance, disutilities, and cost. Limitation: Few surveillance outcome data exist. Conclusion: The model suggests that high-intensity surveillance as recommended in the United States provides modest but clinically relevant benefits over low-intensity surveillance at acceptable cost. Primary Funding Source: National Cancer Institute.
Authors: David A Lieberman; Douglas K Rex; Sidney J Winawer; Francis M Giardiello; David A Johnson; Theodore R Levin Journal: Gastroenterology Date: 2012-07-03 Impact factor: 22.682
Authors: Paul F Pinsky; Robert E Schoen; Joel L Weissfeld; Timothy Church; Lance A Yokochi; V Paul Doria-Rose; Philip Prorok Journal: Clin Gastroenterol Hepatol Date: 2008-07-26 Impact factor: 11.382
Authors: David A Lieberman; David G Weiss; William V Harford; Dennis J Ahnen; Dawn Provenzale; Stephen J Sontag; Thomas G Schnell; Gregorio Chejfec; Donald R Campbell; Jayashri Kidao; John H Bond; Douglas B Nelson; George Triadafilopoulos; Francisco C Ramirez; Judith F Collins; Tiina K Johnston; Kenneth R McQuaid; Harinder Garewal; Richard E Sampliner; Romeo Esquivel; Douglas Robertson Journal: Gastroenterology Date: 2007-10 Impact factor: 22.682
Authors: S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish Journal: N Engl J Med Date: 1993-12-30 Impact factor: 91.245
Authors: Joan L Warren; Carrie N Klabunde; Angela B Mariotto; Angela Meekins; Marie Topor; Martin L Brown; David F Ransohoff Journal: Ann Intern Med Date: 2009-06-16 Impact factor: 25.391
Authors: Felix Wiesmueller; Rolf Schuetz; Melanie Langheinrich; Maximilian Brunner; Georg F Weber; Robert Grützmann; Susanne Merkel; Christian Krautz Journal: Int J Colorectal Dis Date: 2021-01-15 Impact factor: 2.571
Authors: Sidney J Winawer; Ann G Zauber; Michael J O'Brien; Joseph Geenen; Jerome D Waye Journal: Gastrointest Endosc Date: 2020-09-30 Impact factor: 9.427
Authors: Amir-Houshang Omidvari; Iris Lansdorp-Vogelaar; Harry J de Koning; Reinier G S Meester Journal: PLoS One Date: 2021-07-12 Impact factor: 3.752